Janssen enters medical ethics partnership with NYU School of Medicine
Janssen, a subsidiary of Johnson & Johnson (NYSE: JNJ), has undertaken a partnership with the NYU School of Medicine to review requests made to the company for compassionate use of its investigational medicines.
This will begin as a pilot program focused on a single Janssen investigational medicine, with a view to becoming a model applicable more broadly across Johnson & Johnson. Janssen will look to the Division of Medical Ethics for independent advice, ensuring that the evaluation of requests for investigational medicines prior to their approval by the US Food and Drug Administration are treated fairly and ethically.
The NYU School of Medicine will establish the Compassionate-Use Advisory Committee, an external group of internationally recognized medical experts, bioethicists and patient representatives.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze